SRS provides high LC for SCLC BM, including post-PCI/WBRT recurrences. OS remains limited by systemic progression. Prescription dose ≥20 Gy or staged SRS should be considered when feasible.
Building similarity graph...
Analyzing shared references across papers
Loading...
Anirudh Bommireddy
L. Angelov
John H. Suh
American Journal of Clinical Oncology
Cleveland Clinic
Building similarity graph...
Analyzing shared references across papers
Loading...
Bommireddy et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69df2c77e4eeef8a2a6b18df — DOI: https://doi.org/10.1097/coc.0000000000001325